AKEBIA THERAPEUTICS, INC. Proceeds from Issuance of Debt
AKEBIA THERAPEUTICS, INC. (AKBA) reported Proceeds from Issuance of Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2026-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2025-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2025-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2025 was $10.00M, a 77.78% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2024 was $45.00M.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2023 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $10.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $10.00M 10-Q · filed 2025-11-10 | $10.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.00M 10-Q · filed 2026-08-05 | $10.00M derived: sum of 3 quarters · filed 2026-08-05 | $10.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.00M 10-Q · filed 2026-05-07 | $10.00M derived: sum of 2 quarters · filed 2026-05-07 | $10.00M derived: sum of 3 quarters · filed 2026-05-07 | $18.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $8.00M derived: sum of 3 quarters · filed 2026-02-26 | $45.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.00M derived: sum of 2 quarters · filed 2025-11-10 | $45.00M 10-Q · filed 2025-11-10 | $45.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $45.00M 10-Q · filed 2025-08-07 | $45.00M derived: sum of 3 quarters · filed 2026-02-26 | $45.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $37.00M 10-Q · filed 2025-05-08 | $37.00M derived: sum of 2 quarters · filed 2026-02-26 | $37.00M derived: sum of 3 quarters · filed 2026-02-26 | $37.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |